Temporomandibular Joint Pressure Pain Threshold Is Systemically Modulated in Rheumatoid Arthritis

Aims: To investigate the relative importance of systemic and local inflammatory mediators (serotonin: 5-HT; tumor necrosis factor: TNF; soluble interleukin-1 receptor II: IL-1sRII) in the modulation of temporomandibular joint (TMJ) pressure pain threshold in patients with seropositive or seronegative rheumatoid arthritis (RA) and to investigate to what extent TMJ pressure pain threshold is related to other TMJ pain parameters. Methods: Sixty patients with seropositive RA for rheumatoid factor and 74 patients with seronegative RA involving the TMJ were investigated regarding synovial fluid and plasma levels of IL-1sRII, 5-HT, and TNF as well as erythrocyte sedimentation rate, C-reactive protein, thrombocyte particle count, and rheumatoid factor in blood. TMJ resting pain, movement pain, tenderness, and palpebral pain reflex to digital palpation and TMJ pressure pain threshold were examined. Results: Statistical analyses indicated that TMJ pressure pain threshold was only correlated to systemic factors. TMJ movement pain was in turn mainly correlated to systemic mediators in the seropositive patients but to local mediators in the seronegative patients where synovial fluid IL-1sRII was positively correlated to TMJ pain on mouth opening. Seropositive patients had higher systemic inflammatory activity but lower TMJ movement pain intensities than seronegative patients. Conclusion: The results indicate that TMJ pressure pain threshold is modulated by systemic rather than local inflammatory mediators and suggest that it is unrelated or only weakly related to other TMJ pain entities in RA patients. A rheumatoid factor-dependent systemic modulation, in combination with local factors, seems to account for TMJ pain in RA patients.

pain; pain threshold; serotonin; temporomandibular joint; tumor necrosis factor

1. Fredriksson L, Alstergren P, Kopp S. Pressure pain thresholds in the craniofacial region of female patients with rheumatoid arthritis. J Orofac Pain 2003;7:326–332.

2. Rollman B, Lautenbacher S. Sex differences in musculoskeletal pain. Clin J Pain 2001;17:20–24.

3. Fredriksson L, Alstergren P, Kopp S. Serotonergic mechanisms influence the response to glucocorticoid treatment in TMJ arthritis. Mediators Inflamm 2005;4:194–205.

4. Laursen BS, Bajaj P, Olesen AS, Delmar C, Arendt-Nielsen

L. Health related quality of life and quantitative pain measurement in females with chronic non-malignant pain. Eur J Pain 2005;9:267–275.

5. Fredriksson L, Alstergren P, Kopp S. Tumor necrosis factor-alpha in temporomandibular joint synovial fluid predicts treatment effects on pain by intra-articular glucocorticoid treatment. Mediators Inflamm 2006;(6):59425.

6. Syrjanen SM. The temporomandibular joint in rheumatoid arthritis. Acta Radiol Diagn 1985;26:235–243.

7. Tegelberg Å, Kopp S. Subjective symptoms from the stomatognathic system in individuals with rheumatoid arthritis and osteoarthrosis. Swed Dent J 1987;11:11–22.

8. Grassi W, De Angelis R, Lamanna G, Cervini C. The clinical features of rheumatoid arthritis. Eur J Radiol 1998; 27(suppl 1):18–24.

9. Klimiuk PA, Sierakowski S, Latosiewicz R, Cylwik B, Skowronski J, Chwiecko J. Serum cytokines in different histological variants of rheumatoid arthritis. J Rheumatol 2001;28:1211–1217.

10. Kopp S, Alstergren P. Blood serotonin and joint pain in seropositive versus seronegative rheumatoid arthritis. Mediators Inflamm 2002;11:211–217.

11. Neidel J, Schulze M, Lindschau J. Association between degree of bone-erosion and synovial fluid-levels of tumor necrosis factor alpha in the knee-joints of patients with rheumatoid arthritis. Inflamm Res 1995;44:217–221.

12. Symons JA, Young PR, Duff GW. Soluble type II interleukin 1 (IL-1) receptor binds and blocks processing of IL-1 beta precursor and loses affinity for IL-1 receptor antagonist. Proc Natl Acad Sci USA 1995;92:1714–1718.

13. Alstergren P, Benavente C, Kopp S. Interleukin-1beta, interleukin-1 receptor antagonist, and interleukin-1 soluble receptor II in temporomandibular joint synovial fluid from patients with chronic polyarthritides. J Oral Maxillofac Surg 2003;61:1171–1178.

14. Akaogi J, Nozaki T, Satoh M, Yamada H. Role of PGE2 and EP receptors in the pathogenesis of rheumatoid arthritis and as a novel therapeutic strategy. Endocr Metab Immune Disord Drug Targets 2006;6:383–394.

15. McNearney T, Baethge BA, Cao S, Alam R, Lisse JR, Westlund KN. Excitatory amino acids, TNF-alpha, and chemokine levels in synovial fluids of patients with active arthropathies. Clin Exp Immunol 2004;137:621–627.

16. Kopp S, Alstergren P, Ernestam S, Nordahl S, Morin P, Bratt J. Reduction of temporomandibular joint pain after treatment with a combination of methotrexate and infliximab is associated with changes in synovial fluid and plasma cytokines in rheumatoid arthritis. Cells Tissues Organs 2005;180:22–30.

17. Kopp S, Alstergren P, Ernestam S, Nordahl S, Bratt J. Interleukin-1 beta influences the effect of infliximab on temporomandibular joint pain in rheumatoid arthritis. Scand J Rheumatol 2006;35:182–188.

18. Hakala M, Sajanti E, Ikäheimo I, Aho K. High prevalence of rheumatoid factor in community-based series of patients with rheumatoid arthritis meeting the new (1987) ARA criteria: RF-negative non-erosive rheumatoid arthritis is very rare. Scand J Rheumatol 1998;27:368–372.

19. Bukhari M, Lunt M, Harrison BJ, Scott DGI, Symmons DPM, Silman AJ. Rheumatoid factor is the major predictor of increasing severity of radiographic erosions in rheumatoid arthritis: Results from the Norfolk Arthritis Register Study, a large inception cohort. Arthritis Rheum 2002;46:906–912.

20. Scott DL. Prognosis and clinical course. In: Haynes BF, Pisetsky DS, St Clair EW (eds). Rheumatoid Arthritis. Philadelphia: Lippincott Williams & Wilkins, 2004: 26–41.

21. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315–324.

22. Isselée H, De Laat A, Bogaerts K, Lysens R. Short-term reproducibility of pressure pain thresholds in masticatory muscles measured with a new algometer. J Orofac Pain 1998;12:203–209.

23. Fredriksson L, Alstergren P, Kopp S. Absolute and relative facial pressure-pain thresholds in healthy individuals. J Orofac Pain 2000;14:98–104.

24. Alstergren, P, Kopp S, Theodorsson E. Synovial fluid sampling from the temporomandibular joint: Sample quality criteria and levels of interleukin-1 beta and serotonin. Acta Odontol Scand 1999;57:6–22.

25. Voog O, Alstergren P, Leibur E, Kallikorm R, Kopp S. Immediate effects of the serotonin antagonist granisetron on temporomandibular joint pain in patients with systemic inflammatory disorders. Life Sci 2000;68: 591–602.

26. Alstergren P, Kopp S. Pain and synovial fluid concentration of serotonin in arthritic temporomandibular joints. Pain 1997;72:137–143.

27. Nordahl S, Alstergren P, Kopp S. Tumor necrosis factor-alpha in synovial fluid and plasma from patients with chronic connective tissue disease and its relation to temporomandibular joint pain. J Oral Maxillofac Surg 2000; 58:525–530.

28. Zeller J, Weissbarth E, Baruth B, Mielke H, Deicher H. Serotonin content of platelets in inflammatory rheumatic diseases. Correlation with clinical activity. Arthritis Rheum 1983;26:532–540.

29. Endresen GK. Evidence for activation of platelets in the synovial fluid from patients with rheumatoid arthritis. Rheumatol Int 1989;9:19–24.

30. Tegelberg Å, Kopp S, Huddenius K, Forssman L. Relationship between disorder in the stomatognathic system and general joint involvement in individuals with rheumatoid arthritis. Acta Odontol Scand 1987;45:391–398.